4 Comments

What are your views based on the latest Evome earnings? Is the thesis still intact?

Expand full comment

I just had a call with management. Yeah I think the thesis remains pretty much the same. They bounced back from a weaker Q1 and showed positive EBITDA again in Q2. The goal remains to sell two non-core assets (DaMar and South Dakota Partners) to clean up the debt. They have several growth opportunities with their remaining core asset, Biodex. It might take another six months or so to finish cleaning everything up. Until then, the situation might remain somewhat unclear and perceived as risky by the market.

Expand full comment

Thanks, would you happen to have the recording you can share from your call with management?

Expand full comment

I don't, but they're doing an investor webinar next Monday. If you want to get an update and ask questions it will be a great opportunity!

Expand full comment